A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma

Background & aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible patients who had progressed or were intolerant to sorafenib received esca...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2024-04-01
Colecção:	JHEP Reports
Assuntos:	Capmatinib Spartalizumab Hepatocellular carcinoma MET anti-programmed death-ligand 1
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2589555924000223
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!